Literature DB >> 1370075

Intracellular metabolism of 5-formyl tetrahydrofolate in human breast and colon cell lines.

D M Boarman1, C J Allegra.   

Abstract

This report describes the intracellular metabolism of 5-formyltetrahydrofolate into the various one-carbon substituted folate and polyglutamate pools in a human breast (MCF-7) and colon (HCT 116) carcinoma cell line. Metabolism into the one-carbon substituted pools was found to be time and dose dependent over a concentration range up to 50 microM. A 3-fold increase in total intracellular folate was noted over a 50-fold concentration range (1-50 microM) of 5-formyltetrahydrofolate tested in the colon cell line, while in the breast line, a 6-fold increase was detected over a 500-fold concentration range (0.1-50 microM). The level of 5, 10-methylenetetrahydrofolate, which was detectable only in the breast cell line, was found to increase by a factor of 10 (1.8 pmol/mg to 17.9 pmol/mg) over the concentration range studied. The majority of metabolism was into the 10-formyltetrahydrofolate and tetrahydrofolate pools in the breast cells and into the 5-methyltetrahydrofolate pool in the colon cells. Polyglutamation was also time and dose dependent, with a significant proportion of the total pool represented by the higher polyglutamate forms (Glu3-Glu5) after 24 h of continuous exposure to 5-formyl tetrahydrofolate. Pentaglutamate was the highest level noted in both cell lines. The intracellular half-life of the polyglutamate forms was inversely related to the length of the polyglutamate tail with half-lives of 71, 131, 143, 441, and 1167 min for the mono- through pentaglutamate, respectively. Finally, up to a 20:1 ratio of the biologically inactive (6R) isomer to active (6S) isomer of 5-formyltetrahydrofolate resulted in no effect on metabolism into the one-carbon substituted folate pools and only minimal decreases in metabolism to the polyglutamate forms. These studies suggest that prolonged exposure to even relatively low doses of 5-formyltetrahydrofolate may be optimal for intracellular metabolism to the most biologically relevant forms for ternary complex formation with thymidylate synthase and fluorodeoxyuradylate, since longer exposures result in a greater accumulation of the higher polyglutamates.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1370075

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin.

Authors:  Famke L Schneiders; H Pieter van den Berg; Godefridus J Peters; Henk M W Verheul; Hans J van der Vliet
Journal:  Med Oncol       Date:  2010-06-22       Impact factor: 3.064

2.  A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.

Authors:  S Laohavinij; S R Wedge; M J Lind; N Bailey; A Humphreys; M Proctor; F Chapman; D Simmons; A Oakley; L Robson; L Gumbrell; G A Taylor; H D Thomas; A V Boddy; D R Newell; A H Calvert
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

3.  Pharmacologic modulation of 5-fluorouracil by folinic acid and pyridoxine for treatment of patients with advanced breast carcinoma.

Authors:  David Machover; Emma Goldschmidt; Wathek Almohamad; Vincent Castagné; Julien Dairou; Christophe Desterke; Léa Gomez; Yann Gaston-Mathé; Claude Boucheix
Journal:  Sci Rep       Date:  2022-05-31       Impact factor: 4.996

4.  Preemptive leucovorin administration minimizes pralatrexate toxicity without sacrificing efficacy.

Authors:  Ellen Koch; Sara K Story; Larisa J Geskin
Journal:  Leuk Lymphoma       Date:  2013-04-08

5.  A phase II and pharmacokinetic study of 6S-leucovorin plus 5-fluorouracil in patient with colorectal carcinoma.

Authors:  N J Meropol; N J Petrelli; Y M Rustum; M Rodriguez-Bigas; L E Blumenson; C Frank; E Berghorn; P J Creaven
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

6.  Intracellular metabolism of 5-methyltetrahydrofolate and 5-formyltetrahydrofolate in a human breast-cancer cell line.

Authors:  D M Voeller; C J Allegra
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Phase 1 dose de-escalation trial of the endogenous folate [6R]-5,10-methylene tetrahydrofolate in combination with fixed-dose pemetrexed as neoadjuvant therapy in patients with resectable rectal cancer.

Authors:  Bengt Gustavsson; Göran Carlsson; Torbjörn Swartling; Göran Kurlberg; Kristoffer Derwinger; Hillevi Björkqvist; Elisabeth Odin; Fernando Gibson
Journal:  Invest New Drugs       Date:  2015-07-21       Impact factor: 3.850

8.  Pharmacologic modulation of 5-fluorouracil by folinic acid and high-dose pyridoxine for treatment of patients with digestive tract carcinomas.

Authors:  David Machover; Wathek Almohamad; Vincent Castagné; Christophe Desterke; Léa Gomez; Yann Gaston-Mathé; Claude Boucheix; Emma Goldschmidt
Journal:  Sci Rep       Date:  2021-06-16       Impact factor: 4.379

9.  The effect of dose and interval between 5-fluorouracil and leucovorin on the formation of thymidylate synthase ternary complex in human cancer cells.

Authors:  J C Drake; D M Voeller; C J Allegra; P G Johnston
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640

10.  Reduced folate and serum vitamin metabolites in patients with rectal carcinoma: an open-label feasibility study of pemetrexed with folic acid and vitamin B12 supplementation.

Authors:  Clemens C Stoffregen; Elisabeth A Odin; Göran U Carlsson; Göran K Kurlberg; Hillevi G Björkqvist; Maria T Tångefjord; Bengt G Gustavsson
Journal:  Anticancer Drugs       Date:  2016-06       Impact factor: 2.248

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.